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Abstract
A cohort of family members with various chronic 
diseases including Crohn’s disease, asthma, complex 
regional pain syndrome, hypothyroidism, type 1 
diabetes mellitus, and lymphangiomatosis and/or 
evidence of infection by Mycobacterium avium subsp. 
paratuberculosis  (MAP) are described in this series 
of case reports. MAP was cultured from the blood 
of three members affected by the first five diseases 
and there was accompanying elevated anti-MAP IgG 
in two members. The patient affected by the sixth 
disease has a markedly elevated anti-MAP titer. The 
two patients affected by the first four diseases have 
been treated with a combination of anti-MAP antibiotics 
and ultraviolet blood irradiation therapy with resolution 
of the disease symptomatology and inability to 
culture MAP in post treatment blood samples. These 
case reports of patients with MAP infections provide 
supportive evidence of a pathogenic role of MAP in 
humans.
Key words: Crohn’s disease; Complex regional pain 
syndrome; Lymphangiomatosis; Mycobacterium avium 
paratuberculosis ; Cure
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: Five patients with multiple diseases of unknown 
etiology were found to have evidence of infection by 
Mycobacterium avium  subsp. paratuberculosis  (MAP) 
including positive blood cultures (except in case 4). Two 
of the cases (case 1 with Crohn’s disease and asthma 
and case 2 with complex regional pain syndrome, 
hypothyroidism and Raynaud’s phenomenon) have been 
treated with a combination of anti-MAP antibiotics and 
ultraviolet blood irradiation therapy with resolution of 
the disease symptomatology and inability to culture MAP 
in post treatment blood samples. These case reports of 
patients with MAP infections provide supportive evidence 
of a pathogenic role of MAP in humans.
Kuenstner JT, Chamberlin W, Naser SA, Collins MT, Dow CT, 
Aitken JM, Weg S, Telega G, John K, Haas D, Eckstein TM, Kali 
M, Welch C, Petrie T. Resolution of Crohn’s disease and complex 
regional pain syndrome following treatment of paratuberculosis. 




In 1998, David Relman described features of a 
number of poorly understood clinical syndromes 
that strongly indicate a microbial etiology. His list 
of chronic inflammatory diseases with possible 
microbial etiologies included sarcoidosis, inflammatory 
bowel disease, rheumatoid arthritis, systemic lupus 
erythematosus, Wegener granulomatosis, diabetes 
mellitus, primary biliary cirrhosis, tropical sprue and 
Kawasaki disease[1]. He noted that molecular methods 
of microbial identification offer an alternative when 
culture based microbial detection methods fail. His 
prediction regarding the emerging importance of 
molecular methods has proven correct since the 
combination of molecular methods of microbial 
detection and improvements in culture methods has 
led to advances in the field of paratuberculosis. 
Mycobacterium avium subsp. paratuberculosis 
(MAP) is a bacterium that causes Johne’s disease, a 
chronic diarrheal wasting disease in cattle[2] and sub-
human primates[3] and a chronic wasting disease 
in sheep and goats[2]. In Johne’s disease, it is well 
documented that once an animal is infected with MAP, 
the MAP bacterium grows and multiplies inside the 
macrophages of the immune system. The organism is 
excreted in the feces, and to a lesser extent in milk[2]. 
Outside the host animal, MAP multiplies poorly, but 
can survive for extended periods in the environment 
because of its resistance to heat, cold and the effect 
of drying[2]. This slow-growing bacterium affects 
the ileum and causes diarrhea and cachexia. There 
are anecdotal reports of Johne’s disease in which 
prolonged administration of antibiotics resulted in 
suppression but not cure of the disease[4].
The viable bacterium has been found in commercially 
available pasteurized milk[5,6]. Ellingson et al[6] reported 
that 2.7% of retail pasteurized milk samples purchased 
in Wisconsin, Minnesota and California contained 
viable MAP. Because of the presence of this organism 
in the food supply, it would not be surprising if MAP 
is widespread in the environment and the human 
population. The first mass screening study for evidence 
of MAP infection in humans was done in North India on 
serum, blood and stool samples submitted from patients 
with multiple medical conditions including diabetes, 
liver disorders, anemia, thyroid, tuberculosis, typhoid, 
abdominal disorders, inflammatory illness and ion 
imbalance. Singh et al[7] reported that 34% of 23196 
serum samples had anti-MAP antibodies (a comparison 
with normal subjects was not included). The same 
study showed that 12.7% of 1246 blood samples from 
normal healthy individuals had IS900 PCR evidence of 
MAP in their blood and 8.4% of 3093 blood samples 
from patients with the above listed medical conditions 
had PCR evidence of MAP.
It has been suggested for years that there may 
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be an association between Crohn’s disease (CD) 
and Johne’s disease. Dalziel first speculated in 1913 
that chronic enteritis, now known as CD, might be 
caused by MAP[8] and Chiodini first reported the 
culturing of mycobacteria from the intestinal tissues 
of CD patients[9]. For many years, the data were 
conflicting[2,10,11] and the theory that MAP causes CD 
remains controversial[12-14]. Later on, Hermon-Taylor 
and others described a case of a boy with cervical 
lymphadenitis caused by MAP who later developed 
CD[15]. Recent studies show an increase in the detection 
and isolation of MAP in adult Crohn’s patients[16] and 
in children with newly diagnosed CD[17] Meta-analyses 
by Feller et al[18] and Abubakar et al[19] have concluded 
that a majority of studies on the association of MAP 
and CD show that most patients with CD have MAP 
infection. In 2004, Naser et al[20] reported culturing 
MAP from the blood of 50% of patients with CD and 
this work was confirmed in four laboratories including 
the Centers for Disease Control and Prevention[21,22].
In addition, a large, randomized, double-blind, 
placebo-controlled study from Australia showed a 
significant but not lasting response of individuals 
with CD who were treated with antibiotics against 
MAP[23] Apparently unaware that antibiotics fail to 
cure a majority of patients with Mycobacterium 
avium complex infection (MAC)[24], the authors 
incorrectly concluded that because they failed to cure 
patients, CD could not be caused by mycobacterial 
infection. This study and the conclusions of its 
authors were significantly flawed[25,26]. The editorial 
which accompanied the article acknowledged 
that, “subtherapeutic doses of rifabutin (450 mg), 
clarithromycin (750 mg) and clofazimine (50 mg) per 
day were used, whereas the optimal dose of rifabutin, 
clarithromycin and clofazimine for treatment of M 
avium complex infections is 600 mg/d, 1000-2000 
mg/d, and 100 mg/d, respectively”[27]. A recent meta-
analysis of antibiotic trials in CD conducted by Feller 
and coworkers concludes that a substantial benefit was 
evident in trials using nitroimidazoles, clofazimine and 
ciprofloxacin and that a combination of clarithromycin 
and rifamycin and ciprofloxacin should be studied[28].
Most research attention in inflammatory bowel 
disease has focused on the genetics of CD rather than 
the association of the disease with paratuberculosis 
infection. However, these two areas of research 
are probably complementary because the genetic 
mutations, which have been described, may indicate 
increased susceptibility to MAP infection. Also in cattle, 
NOD2 mutations are associated with susceptibility to 
MAP infection[29], and this same mutation has been 
linked to patients with CD. A 2009 study from China 
showed that patients with another mycobacterial 
infection, leprosy, and patients with CD have higher 
rates of the NOD2, TNFSF15 and IL12B mutations 
than healthy controls[30,31]. A large meta-analysis 
genome-wide association study concluded that there 
is considerable overlap between the susceptibility loci 
for IBD and mycobacterial infection[32]. In the only 
simulated human-challenge trial, Israeli researchers 
showed that fetal human small intestine explants in 
mice with severe combined immunodeficiency and 
then inoculated with MAP intraluminally, showed 
invasion of the goblet cells, tissue damage and 
inflammation[33].
In 2006, Dow postulated that MAP may be the 
trigger for type Ⅰ diabetes mellitus (T1DM)[34] because of 
the association of T1DM with mutations of the SLC11a1 
gene[35]. This gene encodes a membrane protein of the 
lysozymes of monocytes and macrophages. Mutations 
in this gene have been associated with susceptibility to 
infectious diseases including tuberculosis and leprosy 
and lead to a more hospitable host environment for 
bacterial survival and replication[36]. Subsequently, 
Sechi and others reported an association of MAP and 
T1DM[37-39]. Recently, Naser et al[40] showed that there is 
a high degree of homology between GAD65 and Hsp65 
which supports a mycobacterial role in the immune 
destruction of the beta cells of the pancreatic islets 
through molecular mimicry.
Additional findings in T1DM also present in other 
mycobacterial infections include elevated angiotensin 
converting enzyme (ACE) levels[41,42] and elevated 
vascular endothelial growth factor (VEGF)[43]. VEGF 
has been reported to be elevated in active pulmonary 
tuberculosis and to decline following successful 
treatment[44]. Some 24.5% of patients with T1DM have 
a positive Saccharomyces cerevisiae Antibody (ASCA) 
test which is similar to the frequency of ASCA positivity 
in Crohn’s disease[45]. Consumption of milk is a risk 
factor for the development of T1DM[46,47].
Frau and others have also reported an association 
of MAP and multiple sclerosis (MS)[48]. Consumption of 
milk is also a risk factor for the development of MS[49].
The following case reports demonstrate an 
association of MAP with several of the above described 
diseases as well as with two diseases which have not 
yet been linked to MAP. In addition, the diseases which 
were treated with anti-MAP therapy resolved.
Assays for evidence of MAP infection
 Three assays were performed on EDTA blood samples 
from each patient (Figure 1). The plasma was assayed 
for antibodies to MAP by ELISA using culture filtrate 
antigens of MAP strain UCF-4 as described[50].
Peripheral blood leukocytes were harvested and 
used for DNA extraction followed by IS900 PCR as 
described[51]. The remainder of the leukocytes were 
inoculated into BACTEC MGIT ParaTB medium with 
supplements but without antibiotics and incubated 
for 6 mo at 37 ℃. After incubation, the culture pellets 
were harvested and subjected to DNA extraction, 
followed by nested IS900 PCR as described[22]. 
Subcultures were done on all PCR-positive MGIT 
cultures to attempt recovery of MAP in pure culture.
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antibody solution were added per well and plates were 
incubated at room temperature for 30 min. Plates were 
washed as before and 100 µL of room temperature 
3,3′,5,5′-tetramethylbenzidine were added per well. 
Plates were incubated at room temperature for 10 min. 
The reaction was stopped by adding 100 µL of 2 mol/L 
sulfuric acid per well. Plates were read at 450 nm using 
an iMark Microplate Reader (BioRad).
CASE REPORT
Case 1
At the Children’s Hospital of Wisconsin, Dr. Grzegorz 
Telega began following a 9-year-old boy who was 
diagnosed with CD in June 2004. He initially presented 
in 2004 with persistent diarrhea, weight loss and 
unexplained fever. His linear growth had slowed 
considerably. Colonscopy and upper gastrointestinal 
endoscopy showed multiple aphthous ulcers in the 
colon, terminal ileum and stomach (Figure 2) and 
biopsies obtained in the colon and gastric antrum 
contained the granulomas of CD (Figure 3). His 
erythrocyte sedimentation rate (ESR) and C reactive 
protein (CRP) were increased.
MAP testing was performed on the patient’s blood. 
The initial sample showed mildly elevated antibody 
titers to one of the MAP antigens, p35, and after 
several months of incubation, MAP was grown from the 
patient’s blood. The second sample drawn more than 
3 mo later showed greater elevations of antibodies to 
Assay for evidence of leprosy
One assay was performed to detect antibodies to M. 
leprae based on phenolic glycolipid-1 antigen. The 
assay was performed as described earlier for Para-
LP-01 based lipid-ELISA for Johne’s disease[52]. Wells 
were coated with 100 ng PGL-1 dissolved in iso-
propanol and dried. Plates were blocked for one hour 
at room temperature with 100 µL 3% BSA (in PBS, pH 
7.4). ELISA was then performed[52]. One hundred µL of 
subject serum diluted 1:20 in 10% FBS/PBS (pH 7.4) 
was added to the wells and incubated for 30 min at 
room temperature. Plates were washed three times with 
PBS followed by adding secondary conjugated antibody 
(sheep anti-human IgH-h+1 HRP conjugated antibody 
diluted 1:2000 in 10% FBS/PBS). 100 µL of secondary 




x 6 mo. @ 37 ℃
Harvest 1 mL
From tube bottom
27 mL for re-testing 
store in freezer
DNA extraction:
yield = 50 µL
23 µL for 1st PCR
1 µL for 2nd PCR
All samples with a positive nested IS900  PCR
Will be sent to a reference lab for sequencing
ELISA for antibodies to MAP
DNA extraction
 + IS900  PCR
Figure 1  Schematic of sample processing and testing methods.
Figure 2  Terminal ileum with multiple ulcers.
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both p35 and p36 antigens and also grew MAP (See 
Table 1 for the summary of MAP testing in this and 
the subsequent 4 cases). During the 3 mo between 
the initial and second sample, the patient’s clinical 
condition steadily worsened with increasing abdominal 
pain and frequency of diarrhea. At the time of the initial 
diagnosis, the patient was 4 feet 8.75 inches or in the 
95th percentile in stature and weighed 71.8 pounds (75th 
percentile). Prior to the onset of illness, his weight 
had previously reached 80 pounds (90th percentile). 
Initially, in August 2004, the patient received 
azathioprine and steroids with concurrent antibiotic 
therapy including clarithromycin and rifabutin, in low 
doses similar to those used in the Australian trial[23]. 
Dr. Telega, the pediatric gastroenterologist, prescribed 
the antibiotics and received consultative advice initially 
from Dr. Hermon-Taylor and later additionally from 
Drs. Chamberlin and Borody. The patient also took 
daily probiotics, which were administered at mid-day. 
After 7 d of antibiotic therapy, as predicted by Dr. John 
Hermon-Taylor the patient developed a mild fever that 
lasted for several days, which Dr. Hermon-Taylor had 
previously observed in other patients and compared to 
a Jarish Herxheimer reaction. Because of an elevated 
ALT and AST, the azathioprine was discontinued in 
Table 1  Summary of Mycobacterium avium subsp. paratuberculosis  antibody, PCR and culture results for cases 1 through 5
Case 1 Case 2 Case 3 Case 4 Case 5
MAP Ab 5/11/04 11/6/12 1/14/13 3/14/13 1/10/13
p35-0.25 ELISA S/P ELISA S/P ELISA S/P ELISA S/P
p36-0.16 1.24 0.49 1.72 0.15
MAP PCR 5/11/04 11/6/12 1/14/13 3/14/13 1/10/13
negative negative negative negative negative
MAP culture 5/11/04 11/6/12 1/14/13 3/14/13 1/10/13
positive negative negative negative positive
MAP Ab 8/18/04 11/20/12 Month/year-
p35-0.5 ELISA S/P pending
p36-0.3 1.31
MAP PCR 8/18/04 11/20/12 Month/year-
negative negative pending
MAP culture 8/18/04 11/20/12 1/18/13 Month/year-





MAP Ab 9/20/04 4/17/13
p35-0.33 ELISA S/P
p36-0.22 1.20
MAP PCR 9/20/04 4/17/13
negative negative
MAP culture 9/20/04 4/17/13
positive negative
MAP Ab 7/9/07 5/7/14
negative ELISA S/P
1.69
MAP PCR 7/9/07 5/7/14
negative negative









MAP: Mycobacterium avium subsp. Paratuberculosis.
Figure 3  Biopsy from the colon showing a granuloma of Crohn’s disease.
100 µm
Kuenstner JT et al . Diagnosis and treatment of paratuberculosis
4053 April 7, 2015|Volume 21|Issue 13|WJG|www.wjgnet.com
December 2004. The patient responded favorably to 
the antibiotics for about 8 mo, but by June 2005, he 
became symptomatic and relapsed (a finding similar to 
that of the Australian trial). The period of relapse lasted 
from June 2005 to March 2006 and during this time 
he remained on low dose antibiotics. A colonoscopy on 
January 11, 2006 showed multiple aphthous ulcers in 
the colon and his weight on that day was 77.3 pounds 
(35 kg). On January 13th a short course of prednisone 
was initiated at a dose of 10 mg/d. On January 15th, 
the dose of prednisone was increased to 20 mg/d. By 
February 11th, his weight was 90 pounds (41 kg).
In late 2005, in addition to receiving antibiotics, 
over the course of a three-month period, the patient 
received a total of 11 once weekly ultraviolet blood 
irradiation (UVBI) treatments which were performed 
by Dr. Mitchell Kurk at his office in Long Island, New 
York. A similar UVBI device has been successfully 
advanced through phase Ⅱ clinical trials at the FDA. 
In addition to UVBI therapy, on advice from 
experts, the doses of clarithromycin and rifabutin were 
increased and ciprofloxacin was added to the regimen. 
On January 13, 2006, the patient was started on 
ciprofloxacin at a dose of 125 mg taken twice per day 
(7 mg/kg per day) and two weeks later this dose was 
increased to 250 mg taken twice per day (14 mg/kg 
per day). On February 12, 2006, when the patient 
weighed 90 pounds (41 kg) the dose of clarithromycin 
was increased to 750 mg, 500 mg taken in the am 
and 250 mg taken in the pm (18 mg/kg per day) and 
the dose of rifabutin was increased to 450 mg taken 
150 mg in the am and 300 mg in the pm (11 mg/kg 
per day). In May 2006, after the patient was in clinical 
remission, clofazimine (an antibiotic with restricted use 
in the United States which is used for the treatment 
of leprosy and Mycobacterium avium complex) was 
added at a dose of 50 mg taken once daily. The 
clofazimine was obtained from a source in Australia.
The patient had a history of seasonal (triggered by 
pollen) asthma beginning at age 3 years and the last 
episode of asthma he has experienced was in April 
2006. 
These antibiotics have been used in many prior 
studies to treat MAP in humans. The doses in this 
patient were adjusted over time. He received over 4 
years of continuous antibiotic therapy until January 
2009. From January 2009, he was on cycled therapy 
of rifabutin, ciprofloxacin and clarithromycin until May 
2011. The patient has been in complete remission 
since April 2006. 
Since May 2011, he has received no medications 
of any type and he has been without any signs or 
symptoms of CD and is now 5 feet 10.5 inches and 185 
pounds (84.1 kg). A follow-up blood culture for MAP 
in July 2007 failed to recover MAP by culture or detect 
MAP DNA by PCR and he tested negative for anti- MAP 
antibody. Currently, he has a normal blood count and 
is negative for inflammatory markers including ESR 
and CRP. A colonoscopy and upper gastrointestinal 
endoscopy in August, 2014 were normal. There are 
many reports in the literature of patients with CD who 
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Figure 4  Family pedigree summarizing history of mycobacterial infection and other diseases of cases 1 through 5 and additional family members.
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Case 2
In early 2012, the sibling of case 1, a 23-year-old 
female began experiencing symptoms initially thought 
to be carpal tunnel syndrome and by August 2012, 
developed Raynaud’s phenomenon in both hands. 
She had a several year history of hypothyroidism and 
was on thyroid hormone replacement. The symptoms 
of neuralgia and paresthesia progressively advanced 
and involved her bilateral hands, elbows, shoulders, 
neck, legs and feet. By the time she was seen at the 
Cleveland Clinic Neurological Center for Pain in late 
November, the physician who examined her noted 
Raynaud’s phenomenon in both hands and described 
the purple color change and cold temperature as 
profound. 
Her workup included a normal EMG study, 
normal CT scan of the brain, and normal values for 
procalcitonin, ESR, CRP, IL-6, ASCA IgA and IgG, 
rheumatoid factor, ANA, SS-A/RO, SS-B/LA, SCL, RNP, 
SM, CCP, JO-1, Centromere antibodies, Anti-Hu TTG-
IgA, lyme serology, gliadin peptide IgA and IgG, anti-
endomysial IgA, serum MPA IgG, MPA IgA, MPA IgM, 
MPA kappa, MPA lambda, MPA kappa/lambda ratio, 
glutamic acid decarboxylase antibody and ganglioside 
antibody studies. Because of a history of travel to 
Guatamala 5 years prior to the onset of her illness, the 
patient’s blood was tested for antibody to M. leprae. 
The PGL-1 assay was negative. The initial diagnosis 
at the Cleveland Clinic was hypersensitivity syndrome 
and the patient was referred to the Cleveland Clinic 
Neurological Center for Pain where she received the 
diagnosis of thoracic outlet syndrome with probable 
evolving complex regional pain syndrome (CRPS). 
Recommendations for therapy included physical 
therapy, muscle relaxants and gabapentin. Gabapentin 
at the lowest recommended dose made her very dizzy 
and therefore, she discontinued this medication. The 
patient obtained multiple sessions of physical therapy 
which were beneficial and engaged in gradually 
increasing regular exercise including walking and 
swimming as tolerated. In December 2012, she could 
only walk 300 feet or tread water wearing a floatation 
device for 5 min. The cause of this condition is 
unknown.
Due to suspicion that CRPS could be a manifestation 
of a MAP infection, blood samples were tested for 
evidence of MAP infection; the first blood sample 
was obtained November 6, 2012 and the second on 
November 20, 2012. The results of the MAP ELISA 
assays from both samples showed significantly 
elevated titers, S/P values of 1.24 and 1.31 
respectively, where the positive control serum was 
from a veterinarian who had accidentally injected 
himself with the MAP vaccine. The MAP PCR tests were 
both negative. MAP was detected by culture from the 
second blood sample. There was rapid progression 
of clinical disease between November 6, 2012 when 
her MAP antibody titer was 1.24 and the organism 
could not be cultured while she had monocytosis and 
lymphocytosis and November 20, 2012 when her 
antibody titer increased to 1.31 and the organism could 
now be cultured while she no longer had monocytosis 
and lymphocytosis. During this two week period she 
developed generalized extreme hypersensitivity to 
minor tactile stimuli. MAP experts were consulted and 
appropriate antibiotics were prescribed.
Other diagnostic test results included elevated 
cryoglobulins of 57 (normal 0-50 ug/mL) and ACE 
level of 59 (normal 8-53 U/L). Cryoglobulins [57-59] and 
ACE[60,61] are elevated in other mycobacterial infections 
including tuberculosis and leprosy. Prior to the onset 
of disease and the initiation of therapy, the patient 
had persistent relative lymphocytosis and eosinophilia 
which was present as early as 1997. Relative lym-
phocytosis has been described in tuberculosis[62]. 
Neurologic findings are not uncommon in CD[63]. In 
addition, siblings of patients with CD are at much higher 
risk of developing CD than the general population[64].
In mid December 2012, the patient was placed on 
anti-MAP therapy and supplementary Vitamin A and 
Vitamin D similar to that administered to her brother. 
Her height and weight are 5 feet 9.5 inches and 150 
pounds (68.2 kg), respectively and her antibiotic doses 
were as follows: Clarithromycin 500 mg twice daily 
(15 mg/kg per day), rifampin 300 mg twice daily (9 
mg/kg per day), levofloxacin 500 mg per day (7 mg/
kg per day) and clofazimine 100 mg 3 times per week 
(4 mg/kg per week). Four days after the initiation of 
therapy she experienced a mild fever which lasted two 
days. Dr. Stuart Weg performed 12 UVBI treatments 
at weekly intervals for 3 mo from January through 
early April 2013. Previously, Weg speculated that CRPS 
is due to an infection caused by a cell wall deficient 
bacterium[65].
Dr. David Haas of the University of Charleston 
Chemistry Department, confirmed by gas chro-
matography, mass spectroscopy, ultraviolet absorption 
spectroscopy and infrared spectroscopy that the 
clofazimine, which was imported from India, was not a 
counterfeit drug.
Following the initiation of therapy, she developed 
monocytosis and the relative lymphocytosis persisted. 
Since that time, she has shown marked clinical im-
provement including disappearance of the generalized 
hypersensitivity, disappearance of the previously 
grossly visible Raynaud’s phenomenon in her hands, 
and improved ability to perform motor skills with a 
reduction in reported pain. By the fall of 2014, she could 
swim one mile or walk five miles per day. Although 
her general condition has greatly improved including 
absence of the generalized extreme hypersensitivity, 
she still experiences episodes of migratory pain. With 
treatment of leprosy, reversal reactions and prolonged 
neuralgia have been observed[66].
Six weeks after beginning the anti-MAP therapy, 
while still taking supplemental thyroxine, she began 
experiencing palpitations and it was noted that her 
TSH had dropped to the low normal range. On the 
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presumption that the palpitations indicated that her 
thyroid function was recovering, in January 2013, she 
stopped supplemental thyroxine, has not experienced 
symptoms of hypothyroidism, and her TSH is now in 
the normal range. A TSH from May 7, 2014 was 4.06 
µIU/mL (reference range 0.350-5.55 µIU/mL). An ACE 
level from May 7, 2014 was still elevated at 58 U/L 
and a complete blood count from the same day was 
normal except for mild monocytosis of 9.3 % (reference 
range 0%-8%) and eosinophilia of 9.5% (reference 
range 0%-4%). By October 14, 2014, a complete 
blood count and differential were normal.
After four months of therapy (April 7, 2013), a 
follow-up blood culture for MAP showed a minimally 
decreased MAP ELISA S/P value of 1.2, the MAP PCR 
test was negative and MAP could not be cultured from 
this sample. A follow-up cryoglobulin study obtained 
from April 17, 2013 was negative after 4 h and 
positive after 72 h. In early January 2014, the patient 
consulted Dr. Kuruvilla John who has since that time 
followed her case. 
Case 3
Since two siblings had evidence of MAP infections 
and responded to anti-MAP therapy, other relatives 
were tested. The paternal uncle of cases 1 and 2, who 
has longstanding T1DM, is also infected with MAP. In 
addition, the uncle was found to have elevated ASCA 
IgA, a serologic marker, which is present in T1DM and 
CD[45]. The uncle’s MAP serum antibody S/P value was 
0.49 (negative). The patient has declined treatment 
for MAP.
Case 4 
The nephew of the mother of cases 1 and 2 has 
lymphangiomatosis, a disease of unknown etiology. 
His blood showed a MAP ELISA antibody S/P value 
of 1.72 (exceptionally high). His MAP PCR and MAP 
culture results were negative. He had a very elevated 
VEGF of 506 pg/mL (reference range of 31-86 pg/
mL), mild monocytosis of 992 (reference range of 
200-950 cells/uL) and a normal neopterin test, ASCA 
IgA and IgG, and ACE tests. The MAP ELISA study, 
VEGF and monocytosis in this case suggest a possible 
mycobacterial causation of lymphangiomatosis and 
further study is indicated. 
Case 5
The father of cases 1 and 2 was tested for MAP 
infection. After 6 mo of incubation, MAP was grown 
from his blood. His MAP PCR on PBMCs was negative 
and his MAP ELISA antibody S/P value was 0.15 
(negative). He is healthy but suffered from seasonal 
asthma (triggered by pollen) at age 12 years and 
also while living in Germany from 1986 to 1989. In 
addition, he has rosacea, which was diagnosed by 
clinical signs and a skin biopsy showing non-caseating 
granulomas. This condition is treated with a topical 
ointment containing azelaic acid. In 2004, his blood 
was found positive for antibodies to p35 and p36 MAP 
antigens.
Because of the devastating nature of the diseases 
in case 1 and case 2 and the poor record of efficacy, 
standard therapies were eschewed. Institutional 
review board (IRB) approval was not sought since the 
law allows off label use of FDA approved drugs and 
also allows the administration of UVBI in New York. 
IRB approval is generally not required in the care of 
individual patients. In cases 1 through 3, infectious 
disease specialists were consulted and informed about 
the elevated MAP ELISA antibody titers and/or positive 
MAP cultures but declined to make recommendations 
regarding therapy. 
Additional family members were tested for evidence 
of MAP infection as well. The mother of case 1 and 
case 2 was negative for MAP by PCR on PBMC and 
culture, and had an ELISA S/P of 0.08 (negative). 
The brother of case 1 and case 2 had a negative 
MAP PCR and negative culture and ELISA S/P of 0.59 
(slightly elevated). The maternal grandfather of case 
1 and case 2 had a negative MAP PCR on PBMCs and 
negative culture and an ELISA S/P of 0.13 (negative). 
The maternal grandmother (with hypothyroidism) of 
case 1 and case 2 had a negative MAP PCR on PBMCs 
and negative MAP culture and an ELISA S/P of 0.0 
(negative). 
The families of both parents of case 1 and case 
2 have a history of susceptibility to mycobacterial 
infection. Figure 4 which is a family pedigree sum-
marizing the cases and the mycobacterial infection and 
other disease history in other members. 
DISCUSSION
The presence of viable MAP in the blood of a majority 
of CD patients is an important finding which has been 
previously reported by Naser[20,22]. Some observers 
ascribe this phenomenon to the “leaky bowel” resulting 
from mucosal disruption in CD[67]. In case 1, the 
recovery of the viable organism in the setting of two 
diseases and the failure to recover the viable organism 
in the absence of these two diseases argues in favor of 
a pathogenic role of MAP in these patients. Similarly, 
in case 2, the recovery of the viable organism in the 
setting of two other diseases and the failure to recover 
the organism in the absence of these two other 
diseases also argues in favor of a pathogenic role of 
MAP. Furthermore, the recovery of the viable organism 
in case 2 in which the patient suffered from CRPS 
cannot be explained by the leaky bowel hypothesis 
since this patient has not experienced bowel related 
symptoms. In addition, a pathogenic role of MAP in the 
human host is likely, considering the zoonotic capacity 
of slow-growing mycobacteria and because this 
organism is an obligate pathogen, i.e., one which does 
not propagate in the environment[68]. 
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A second possible interpretation of the findings in 
these case reports is that the diseases were not caused 
by MAP and went into remission spontaneously. In the 
consideration of the probable events in case 1 and case 
2, the percentage of patients who experience long term 
remissions in CD, CRPS, hypothyroidism and Raynaud’s 
phenomenon is 10%[69], 74%[70], 62%[71], and 64%[72], 
respectively. With the assumption that case 1 and 
case 2 resolved spontaneously, the outcome follows 
the likelihood function. The probability of spontaneous 
resolution in case 1 is 0.10 and in case 2 is 0.30 (0.74 × 
0.62 × 0.64 = 0.30) and the probability of spontaneous 
resolution in both patients is 0.10 × 0.30 or 0.03 which 
is very unlikely. Controlled clinical trials of anti-MAP 
therapy are necessary to determine whether these 
case reports are reproducible. Clinical trials have been 
designed and funding is being sought. 
A third possible interpretation of the recovery of 
MAP from the blood samples in case 1 and in case 
2, is that the MAP organism is a contaminant from 
specimen processing. This interpretation is unlikely 
since in both cases there are increased antibodies 
directed against MAP indicating a host response to the 
organism. The presence of elevated serologic markers 
which are associated with mycobacterial infection, 
including CRP in case 1 and ACE in case 2, also weighs 
against this possibility. 
We believe that the profound long lasting remission 
in case 1 resulted from anti-MAP therapy and is unlikely 
due to steroid administration, since such remissions 
rarely result from steroid administration alone. Based 
on these anecdotal reports, three additional cases of 
children with CD and MAP infection treated successfully 
with combination anti-MAP antibiotics and UVBI 
(personal communication), open label trials in CD, 
and controlled trials in MAC infection, we recommend 
the use of three antibiotics including clarithromycin, 
rifampin and levofloxacin (at 15, 9 and 7, respectively, 
mg/kg per day) for at least two years in combination 
with periodic UVBI (if available). However, at this time, 
the optimal antibiotic combination is unknown.
In cases 1 and 2, the rapid progression of the 
disease accompanied by an increase in antibodies to 
MAP antigens between the first two specimens may 
mirror Johne’s disease in dairy cattle in which the 
progression in the severity of disease and the degree 
of mycobacterial colonization coincides with a switch 
from the TH1 to TH2 type immune response[73].
The presence of the viable bacterium in the blood 
of an apparently healthy host (case 5) is an interesting 
finding. Apparently healthy individuals may have less 
virulent forms of disease such as transient childhood 
asthma or rosacea as noted in case 5. In addition, if 
MAP-infected people are followed over a long enough 
period of time, some may eventually develop one of 
the diseases traditionally considered autoimmune. 
It would not be surprising if there is a population 
of individuals who are MAP-infected but never develop 
disease. Mycobacterium tuberculosis, causes active 
disease in only 10% of infected humans[74]. A similar 
situation probably pertains to human paratuberculosis, 
i.e., most MAP infected individuals may never develop 
disease. Clinically normal cattle with known MAP 
infection are common suggesting a parallel in the 
human population[75].
Any theory of causation of the autoimmune 
diseases must explain two consistent observations for 
most of these diseases: (1) the north south gradient 
in geographical distribution of the disease (in the 
northern hemisphere)[76]; and (2) the predominant 
female to male ratio in most of these diseases. The 
first observation is concordant with the worldwide 
distribution of Johne’s disease[77], the lower levels of 
Vitamin D in the human host at northern latitudes[78], 
and the role of Vitamin D in the clinical course of 
patients with CD and T1DM[79,80]. A possible explanation 
for the second observation includes reduced host 
immunity due to the effects of estradiol and/or 
progesterone[81-83]. Future work may shed light on the 
immunology of gender differences with these diseases. 
Because of the known risk of disease progression in 
CD from birth control medication, women who have 
been diagnosed and treated for a MAP infection should 
consider non-hormonal birth control methods. 
The optimal hosts for MAP are ruminants; cattle, 
sheep, and deer, in which, a higher burden of bacteria 
are generally found than in humans. These animals 
have a higher body temperature than humans ranging 
from 100.4 to 102.8, 100.9 to 103.8 to 104 F, for cattle, 
sheep and deer, respectively[84,85]. These differences in 
body temperature suggests that the growth of MAP in 
laboratory culture may be accelerated by raising the 
incubation temperature to 104 F. Further investigation 
of this issue is warranted.
If controlled trials of MAP related illnesses confirm 
the findings of these case reports and the autoimmune 
diseases can be cured, because the bacterium is 
present in the food supply, will treated patients 
redevelop disease on re-exposure to the organism? 
The precautionary principle should apply and improved 
food safety and public health measures are necessary 
to limit human exposure to MAP. Until improved 
measures are in place, treated and cured patients 
should probably avoid known sources of MAP which 
include pasteurized milk and milk products such as 
yoghurt, cheese and ice cream and undercooked beef. 
Open label trials of long-term antibiotic therapy in 
CD have a significant relapse rate. Adjunctive therapy 
such as UVBI combined with appropriate antibiotics 
may be a way to improve therapeutic outcomes. 
UVBI was developed by Knott[86]. In his article on the 
development of ultraviolet blood irradiation, he refers 
to the work of European investigators who “believed 
that most of the systemic reactions observed following 
exposure of the skin to ultraviolet rays were due to 
the influence of the rays upon the blood”[86]. Knott 
was most likely aware of the work of Finsen who 
received the Nobel Prize in 1903, for his work showing 
Kuenstner JT et al . Diagnosis and treatment of paratuberculosis
4057 April 7, 2015|Volume 21|Issue 13|WJG|www.wjgnet.com
the beneficial effects of ultraviolet treatments of the 
skin in patients with lupus vulgaris, i.e., tuberculosis 
of the skin[87]. The Knott device was used for the 
treatment of many infections[88-90]. and while exact 
figures are unavailable, probably thousands of patients 
were treated with this therapy throughout the United 
States. Several studies[91,92] as well as three controlled 
trials from Russia have shown beneficial effects in 
the treatment of tuberculosis[93-95]. Because the Knott 
hemo-irradiator predated the advent of the FDA, this 
device was never FDA approved. However, in recent 
years, UVBI was advanced successfully through 
phase Ⅱ clinical trials for the treatment of hepatitis C 
infection. 
Various studies on UVBI that may explain the 
benefit of this therapy include the following. Ultraviolet 
light in the C region (UVC) inactivates bacterial 
and viral pathogens, present in the blood, which is 
irradiated. In the case of bacteria and DNA viruses, 
UVC induces the formation of thymine-thymine 
dimers, which prevents replication[96]. In the case of 
RNA viruses, UVC induces the formation of uracil-uracil 
dimers which also prevents replication[97]. Bacteria 
including Mycobacterium tuberculosis have UV repair 
mechanisms and normal lymphocytes also have UV 
repair mechanisms[98,99].
Because only 200 cc of blood in an average adult 
(or 4% of the total 5.0 liter blood volume) is treated 
during a single session, factors other than pathogen 
inactivation are likely to explain the potential benefit. 
Ultraviolet light shined on murine fibroblasts results 
in the formation of hydrogen peroxide and hydroxyl 
radicals which are also bactericidal and virucidal[100]. 
Ultraviolet light in the A region and at higher doses 
and exposure durations causes immune suppression, 
but ultraviolet light in the B (UVB) region and UVC 
have been shown to stimulate dendritic cells[101-103]. 
Hemoglobin which has been irradiated with UVB and 
UVC wavelengths exhibits fluorescence[104] and the 
wavelength of light which is emitted, 365 nm, causes 
the formation of DNA or RNA adducts in riboflavin and 
other chromophores and these adducts are bactericidal 
and virucidal[105]. It is now known that in spite of long 
term treatment of tuberculosis by antibiotics, there 
are persisters, which are not killed by the drugs[106,107]. 
Also Mycobacterium avium complex organisms can 
resist the bactericidal activity of clarithromycin within 
the phagosomes of macrophages[108]. Viable MAP 
organisms which have survived the antibiotics by either 
of these routes and which are within macrophages 
may not survive ultraviolet irradiation[68]. An in-vitro 
study showed that monocytes which are irradiated 
with UVB and then infected with Mycobacterium avium 
intracellulare (MAI) organisms, efficiently inhibit the 
intracellular replication of MAI[109]. The authors in this 
work speculated that the intracellular inhibition of MAI 
replication in the UV treated macrophages may be due 
to the induction of intracellular vitamin D production by 
the UVB. 
Vitamin D has been shown to play an important 
role in the host immune response to mycobacterial 
infection[110]. Vitamins A and D have been shown to 
inhibit the growth of MAP in vitro[111]. Vitamin D has 
also been shown to reduce the proliferation of M. 
tuberculosis in macrophages[112]. Activated dendritic 
cells are known to produce Vitamin D[113] and Vitamin 
D induces the intracellular production of cathelicidin, 
which is an antimicrobial protein[114]. High levels of 
Vitamin D have been correlated with a reduced risk of 
developing multiple sclerosis, and Vitamin D intake is 
inversely associated with rheumatoid arthritis (another 
autoimmune condition) and the severity of this latter 
disease also correlates with Vitamin D levels[113].
Finally, many types of cells including leukocytes and, 
in particular, monocytes, exposed to ultraviolet light 
secrete heat shock proteins and these proteins play an 
important role in the response to infection[115-117].
A small open label trial of UVBI in 4 patients with 
severe Raynaud’s syndrome showed clinical improvement 
that lasted for 3 mo in all of the patients and a reduction 
of mycobacterial heat shock protein antibodies in one of 
the patients[118].
These case reports support a pathogenic role of 
MAP in humans. Large controlled trials are indicated 
for many of the autoimmune diseases associated 
with MAP infection including CD, T1DM, MS and CRPS 
using anti-MAP therapy combined with UVBI (perhaps 
substituting ethambutol for ciprofloxacin)[119] in one 
arm and combination infliximab and azathioprine in 
the control arm to determine whether properly dosed 
anti-MAP therapy is more effective than currently 
available therapies. RedHill Biopharma Ltd., Tel Aviv, 
Israel, has initiated phase Ⅲ clinical trials in Europe 
and North America to treat CD and MS using a 
combination therapy of clarithromycin, rifabutin and 
clofazimine[120]. MAP prevalence studies are indicated in 
lymphangiomatosis, ankylosing spondylitis, rheumatoid 
arthritis, hypothyroidism, hyperthyroidism, adrenal 
insufficiency, systemic sclerosis, Sjogren syndrome, 
systemic lupus erythematosus, dermatomyositis, 
psoriasis, sarcoidosis, celiac disease, rosacea, asthma, 
fibromyalgia, amyotrophic lateral sclerosis, myasthenia 
gravis, Parkinson’s disease and Alzheimer’s disease. 
The results of therapeutic trials should be evaluated 
with consideration of the success rate in treating 
Mycobacterium avium complex infections, a mere 
42%[27] and that the treatment of Mycobacterium 
leprae is associated with an absolute relapse rate of 3% 
and that relapses may occur more than 10 years after 
multiple drug therapy has concluded[121].
Researchers who explore the role of MAP in the 
autoimmune diseases should be aware that our 
current diagnostic tests are crude. The ELISA for 
serum antibodies to MAP46 was adapted from the 
cattle assay which has a sensitivity of only 30% to 
40% in cattle which are known to be MAP-infected[122]. 
The suboptimal sensitivity and the variation between 
current serologic assays for MAP make the diagnosis 
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of MAP infection difficult. However, in the presence 
of otherwise unexplained autoimmune disease, the 
occurrence of positive blood cultures for MAP should be 
a significant finding. 
Furthermore, pre-existing therapies for these 
conditions may hinder culture recovery methods. 
Many of the currently used immunomodulators 
have demonstrated bacteriostatic effects on MAP in-
vitro[123,124]. When possible, MAP diagnostic testing 
should be conducted on newly diagnosed patients prior 
to instituting immunosuppressive therapies which can 
inhibit the growth of MAP in cultures. While the blood 
culture method of Naser has been a great advance 
in the field of human paratuberculosis research, it is 
positive in 55% of patients with inflammatory bowel 
disease and in 22% of non-inflammatory bowel 
disease patients[22], and therefore cannot by itself 
serve as a discriminator for the presence or absence 
of disease. Concurrent detection of antibodies directed 
at MAP will probably be helpful in this regard[50]. MAP 
cultures should be performed in laboratories with 
expertise. Parrish et al[125] failed to replicate the blood 
culture study of Naser et al, but their method did not 
include egg yolk in the medium (regarded by many as 
vital for MAP growth) and the cultures were only held 
for 18 wk (MAP cultures for humans are usually held 
for at least 6 mo and up to one year). 
The current MAP ELISA reacts to both host IgM and 
IgG. Modifying the assay into its isotype components, 
i.e., IgM and IgG, may permit a better determination 
of whether the host response reflects active disease or 
remote exposure. Further research is necessary in this 
area.
Should MAP be proven to cause many of the auto-
immune diseases, a potential role in carcinogenesis 
should be explored. Helicobacter pylori is now recognized 
as playing a major role in the pathogenesis of primary 
gastric MALT lymphoma and gastric carcinoma[126]. CD 
patients are known to have increased risk of bowel 
cancer and lymphoma. Whether this increased risk is 
due to the immunosuppressive therapies used in this 
disease or due to infection by MAP is unknown and 
should be investigated further[127]. In summary, much 
more must be learned about this elusive and enigmatic 




Please summarize main symptoms in one sentence. Case 1 had Crohn’s disease 
(CD) and experienced abdominal pain, diarrhea and weight loss while case 2 
had complex regional pain syndrome (CRPS) and experienced generalized 
hypersensitivity, neuralgia, paresthesias and Raynaud’s phenomenon. 
Clinical diagnosis
Please summarize main clinical findings in one sentence. Case 1 had CD while 
case 2 had CRPS.
Differential diagnosis
Please summarize thoughts and methods for differential diagnosis in one 
sentence. The differential diagnosis in case 1 included celiac disease and food 
allergy while the differential diagnosis in case 2 included multiple sclerosis. 
Laboratory diagnosis
Please summarize laboratory testing methods and major findings in one 
sentence. Case 1 had anemia, elevated erythrocyte sedimentation rate, 
CRP and WBC while case 2 had elevated angiotensin converting enzyme, 
cryoglobulins, lymphocyte and eosinophil count and TSH and initially, 
both patients had blood cultures positive for Mycobacterium avium subsp. 
paratuberculosis (MAP). 
Imaging diagnosis
Please summarize imaging methods and major findings in one sentence. Case 
1 had multiple aphthous ulcers on upper gastrointestinal endoscopy and on 
colonoscopy while case 2 had an unremarkable EMG study.
Pathological diagnosis
Please summarize pathological methods and major findings in one sentence. 
Case 1 had granulomas in the gastric and colonic biopsies while case 2 had no 
biopsies. 
Treatment
Please summarize treatments and drugs used in one sentence. Both case 1 
and case 2 received a combination of periodic ultraviolet blood irradiation (UVBI) 
and antibiotics which included clarithromycin, rifampin and ciprofloxacin for at 
least 2 years.
Related reports
Please provide other contents related to the case report to help readers better 
understand the present case.
Term explanation 
Please explain uncommon terms present in the case report. UVBI is ultraviolet 
blood irradiation which consists of periodic irradiation of approximately 200 cc 
of patient blood using ultraviolet light in the B and C regions.
Experiences and lessons
Please summarize experiences and lessons learnt from the case in one 
sentence. Both CD and CRPS, when caused by MAP, resolve when the 
organism is eradicated from the host.
Peer-review
Please summarize the strengths and weaknesses of the article based on the 
reviewers’ comments so that readers can obtain objective knowledge from the 
article. This study is anecdotal and it will be necessary to study large numbers 
of patients in a controlled trial setting to determine whether these results are 
reproducible.
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